BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8822501)

  • 1. Mechanisms of action of endocrine treatment in breast cancer.
    Lønning E; Lien EA
    Crit Rev Oncol Hematol; 1995 Nov; 21(1-3):158-93. PubMed ID: 8822501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine therapy in metastatic breast cancer.
    Kimmick GG; Muss HB
    Cancer Treat Res; 1998; 94():231-54. PubMed ID: 9587691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine resistance: what do we know?
    Miller TW
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel endocrine therapies in breast cancer.
    Klijn JG; Setyono-Han B; Bontenbal M; Seynaeve C; Foekens J
    Acta Oncol; 1996; 35 Suppl 5():30-7. PubMed ID: 9142962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal therapy of breast cancer.
    Locker GY
    Cancer Treat Rev; 1998 Jun; 24(3):221-40. PubMed ID: 9767736
    [No Abstract]   [Full Text] [Related]  

  • 8. Endocrine therapy of endometrial cancer.
    Lentz SS
    Cancer Treat Res; 1998; 94():89-106. PubMed ID: 9587684
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
    Journé F; Body JJ; Leclercq G; Laurent G
    Expert Opin Drug Saf; 2008 May; 7(3):241-58. PubMed ID: 18462183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological rationale for endocrine therapy in breast cancer.
    Miller WR
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):1-32. PubMed ID: 14687595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen and the endometrium.
    Barakat RR
    Cancer Treat Res; 1998; 94():195-207. PubMed ID: 9587689
    [No Abstract]   [Full Text] [Related]  

  • 16. The duration of adjuvant tamoxifen therapy.
    Bilimoria MM; Jordan VC
    Cancer Treat Res; 1998; 94():181-93. PubMed ID: 9587688
    [No Abstract]   [Full Text] [Related]  

  • 17. [Breast neoplasms: predictive factors for endocrine therapy ].
    Hayashi S
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():148-53. PubMed ID: 17682151
    [No Abstract]   [Full Text] [Related]  

  • 18. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
    Frassoldati A; Guarneri V; Conte P
    Cancer Biol Ther; 2009 Aug; 8(15):1456-8. PubMed ID: 19617703
    [No Abstract]   [Full Text] [Related]  

  • 19. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
    Lykkesfeldt AE
    Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.